# Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection

> **NCT05269329** · PHASE2 · COMPLETED · sponsor: **Valenta Pharm JSC** · enrollment: 160 (actual)

## Conditions studied

- Common Cold
- Acute Respiratory Infection
- Influenza, Human

## Interventions

- **DRUG:** XC8, film-coated tablets, 20 mg/day
- **DRUG:** XC8, film-coated tablets, 40 mg/day
- **DRUG:** XC8, film-coated tablets, 80 mg/day
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05269329
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-26
- **Primary completion:** 2021-10-26
- **Final completion:** 2021-10-26
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2022-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05269329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05269329, "Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05269329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*